SCHEMBL19956899

SCHEMBL19956899

CNc1c(NCCc2ccccc2)c(=O)c1=O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.63
KMT2A Q03164 5/20 0.63
CTDSP1 Q9GZU7 1/20 0.59
POLB P06746 2/20 0.55
TAAR1 Q96RJ0 4/20 0.52
ATM Q13315 1/20 0.52
CXCR2 P25025 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.48
PKM P14618 1/20 0.47
MAPK1 P28482 1/20 0.47
FES P07332 1/20 0.47
FGFR1 P11362 1/20 0.47
FLT4 P35916 1/20 0.47
KDR P35968 1/20 0.47
KDM4E B2RXH2 2/20 0.46
GAA P10253 1/20 0.46
APP P05067 1/20 0.44
BCHE P06276 1/20 0.44
ACHE P22303 1/20 0.44
NSD2 O96028 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19956897 0.81 MAPKAPK2 (0.57) MEN1KMT2APOLBCXCR2L3MBTL1
SCHEMBL20927269 0.79 MEN1 (0.63) MEN1KMT2ACTDSP1POLBTAAR1
SCHEMBL16264714 0.77 MEN1 (0.56) MEN1KMT2ACTDSP1POLBTAAR1
SCHEMBL16144154 0.75 KMT2A (0.50) MEN1KMT2ACTDSP1POLBTAAR1
SCHEMBL30673004 0.74 MEN1 (0.62) MEN1KMT2ACTDSP1POLBCXCR2
SCHEMBL4364173 0.74 FLT4 (0.79) MEN1KMT2ACTDSP1CXCR2MAPK1
SCHEMBL8012011 0.72 L3MBTL1 (0.53) MEN1KMT2ACTDSP1POLBTAAR1
SCHEMBL4364819 0.71 MEN1 (0.50) MEN1KMT2ACTDSP1POLBTAAR1
SCHEMBL4374200 0.71 MEN1 (0.54) MEN1KMT2ACTDSP1POLBTAAR1
SCHEMBL18121422 0.70 GRIN2D (0.38) MAPK1KDM4EGAAACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10654808-B2 Tyrosine kinase inhibitor and pharmaceutical composition comprising same Guangdong Raynovent Biotech Co., Ltd. (CN) 2020-05-19 US disclosed
US-20190119217-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Guangdong Raynovent Biotech Co., Ltd. (CN) 2019-04-25 US disclosed
EP-3293177-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2018-03-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190119217-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME ABL1, LCK, ERBB2 MEN1 1450/4885KMT2A 1030/4885CTDSP1 2214/4885
US-10654808-B2 Tyrosine kinase inhibitor and pharmaceutical composition comprising same ABL1, LCK, ERBB2 MEN1 1450/4885KMT2A 1030/4885CTDSP1 2214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.